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Currently there is much excitement in certain quarters about
antisense oligonucleotides, both as the drugs of the future for
treatment of cancer and viral infections, most notably AIDS,
and also as genetic tools for generating mutant phenocopies
without genomic mutation in investigations of mammalian
gene function. The extent of this excitement is reflected in the
proliferation of antisense biotechnology companies, newly
formed with venture capital in eager anticipation of the
imminent bonanza (Klausner, 1990). It is remarkable how
antisense oligonucleotide technology has received publicity in
excess of its present achievements, and there are some, not
directly involved in this area, who have gained the impression
of an established technique, like polymerase chain reaction or
DNA fingerprinting, which may be taken off the shelf and
used as necessity demands. Without wishing to appear
unduly negative, it must be stated that, as yet, antisense
oligonucleotides have not arrived (Tidd, 1990).
The concept of antisense inhibition of gene expression has
gained respectability largely through the elegant efforts of the
molecular geneticists. They have demonstrated that produc-
tion of antisense RNA may be a naturally occurring genetic
control mechanism in prokaryotes. Also, antisense RNA was
shown to induce sequence specific inhibition of target gene
expression when introduced artificially into eukaryotic cells,
either by microinjection of preformed antisense molecules, or
through transfection with DNA plasmid constructs carrying
genes inverted relative to an appropriate transcriptional pro-
moter (Melton, 1988). It is generally assumed that the anti-
sense RNA hybridises with the complementary mRNA to
form a double stranded helix analogous to double stranded
DNA, and in so doing inhibits nuclear processing of the
immature mRNA, transport into the cytoplasm, cytoplasmic
translation into protein or, alternatively, stimulates degrada-
tion of the message. Despite the impressive results of anti-
sense RNA experiments, the actual intracellular mechanism
responsible for the observed effects remains to be determined.
The therapeutic implications of antisense technology are
compelling, in that inhibition of expression of essential viral
genes should selectively curtail viral replication, whereas
functional elimination of the appropriate activated oncogenes
in a cancer cell would be expected to result in the instant
reversal of the process of malignant progession, and might
even trigger entry into a terminal differentiation pathway.
However, the antisense RNA approach suffers from several
shortcomings, namely that the inverted gene constructs are
produced in very small amounts by rather laborious mole-
cular genetic techniques, and the antisense RNA is biosyn-
thesised as if it were an mRNA, where long sequences are
generally the rule. Long antisense RNA sequences will be
insensitive to short mismatches between a normal and
mutant allele, and, consequently, will be of little use in
discriminating between, for example, an activated ras onco-
gene and the normal cellular proto-oncogene. In addition,
the mere thought of treating patients with recombinant
attenuated viruses carrying inverted ras genes may be suffic-
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ient to make many a hardened clinician pale, not least
because of the danger that in vivo recombination could con-
ceivably generate novel pathogenic entities.
On the face of it, therefore, short synthetic antisense oligo-
nucleotides, designed to function in an analogous manner,
would appear to offer several advantages, in that they may
be prepared chemically by straightforward techniques in
comparatively large amounts as sequences with maximum
sensitivity to mismatches between mutant and normal alleles,
they could be administered as conventional drugs, and the
therapeutic efficacy of the molecules could conceivably be
enhanced by modifications to generate analogues of the
parent structure.
What then are the facts about the current state of the art
of the antisense oligonucleotide technology? There is no
doubt that normal phosphodiester antisense oligodeoxynu-
cleotides (i.e. with the normal DNA single strand primary
structure) are able to inhibit translation of target mRNAs
into protein in cell free systems and microinjected oocytes.
For the most part these effects have been attributed to
degradation of the mRNA by ribonuclease H at the site of
hybridisation with the complementary oligodeoxynucleotide
(for review see Tidd, 1990). In the absence of the enzyme,
antisense oligodeoxynucleotides targeted downstream of the
initiation codon of the mRNA are unable to affect protein
synthesis since the fully assembled ribosomal complex is able
to locally destabilise secondary structure in its path as it
proceeds along the message. However, there is some evidence
to suggest that oligodeoxynucleotides complementary to the
initiation codon region or upstream untranslated sequences
may inhibit translation, without the participation of ribo-
nuclease H, by a direct effect on initiation complex forma-
tion. It has not proved possible to observe sequence specific
effects of ablation of maternal mRNAs on the subsequent
embryonic development of microinjected oocytes, because of
the generalised toxicity of the oligodeoxynucleotides at the
concentrations required. The toxicity in turn is almost cer-
tainly the result of the profound biological effects of mono-
meric deoxynucleotides, released in high concentration during
rapid nuclease mediated degradation of the oligodeoxynu-
cleotides. This factor is rarely taken into consideration in
experiments with antisense oligodeoxynucleotides on intact
mammalian cells in culture. Uptake of oligodeoxynucleotides
by intact cells has not been subjected to exhaustive investiga-
tion, and several studies using end labelled molecules have
failed to address the possibility that extracellular degradation
preceeded intracellular accumulation of the label. However,
the results obtained so far would suggest that despite their
polyanionic nature, oligodeoxynucleotides are taken up by at
least some types of mammalian cell. In general, intact cells
accumulated higher concentrations than fixed cells, possibly
by receptor mediated endocytosis, the internal concentration
was always lower than that in the medium, and where
measured, cell associated oligodeoxynucleotides were largely
intact at early times but became progressively degraded.
There have been a large number of papers claiming antisense
effects for exogenous oligodeoxynucleotides on intact cells,
and in several cases activated oncogenes were the targets.
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Not all of these reports were equally convincing, since despite
presenting negative data for sense or nonsense sequence
oligodeoxynucleotide controls, no attempts were made to
monitor the cell uptake or integrity of the oligodeoxynu-
cleotides during the course of the experiments, nor their
effects on the intracellular concentrations of irrelevant pro-
teins with turnover rates similar to those of the target gene
products. Oligodeoxynucleotides are highly susceptible to
degradation by nucleases, not only within cells, but also in
the serum component of the cell culture media (Tidd &
Warenius, 1989), and it is difficult to understand how pro-
longed antisense effects were achieved when the half life of
the intact extracellular molecules was probably 1 h or less.
On the other hand, in some reports, degradation by serum
was anticipated, and cells were treated with oligodeoxynu-
cleotides under serum free conditions (e.g. McManaway et
al., 1990).
Additional potential targets exist in intact cells since it is
possible to select sites involved in nuclear processing of
precursor mRNA molecules which is required to produce
mature translatable species. Oligodeoxynucleotides comple-
mentary to splice sites in precursor mRNA may possibly
inhibit gene expression by blocking the splicing mechanism
without any involvement of ribonuclease H. Surprisingly, no
one has yet established the extent of the participation of
ribonuclease H like activity in the action of oligodeoxynu-
cleotides in intact cells, although it is assumed to be involved,
and there is some evidence for depletion of mRNA which
could result from such a mechanism. This is an important
area for further study since it might prove to be a determin-
ing factor in which cell types are likely to be susceptible to
antisense inhibition of gene expression, as well as being
relevant to the potential efficacy of oligonucleotide analogues
that are unable to activate degradation of RNA by the
enzyme.
It is apparent that poor cell uptake, biological instability
and potential toxicity of their breakdown products preclude
the development of normal phosphodiester oligodeoxynucleo-
tides as therapeutic agents. On the other hand the efficiency
of hybridisation of these molecules, the stability of their
hybrids, and possibly the ability of oligodeoxynucleotides to
activate ribonuclease H degradation of RNA are desirable
properties of an antisense effector. Consequently, attempts
have been made to design structural analogues which retain
these characteristics of the parent molecule, but which exhibit
enhanced resistance to nucleolytic degradation and increased
ability to permeate intact cells (see reviews in Cohen, 1989;
Tidd, 1990). So far it has been very much a case of what was
gained on the roundabouts was lost on the swings, and no
analogue structure yet devised fulfils all the requirements of
an ideal antisense effector even for in vitro cell work, let
alone for development of potential chemotherapeutic agents.
Analogues of oligodeoxynucleotides in which the bases are
present in the a-anomeric configuration, rather than the nor-
mal P-configuration, are nuclease resistant, readily soluble,
and form hybrids with complementary nucleic acid sequences
in which, for most cases, the strands are aligned in parallel
rather than an antiparallel orientation. However, a-oligo-
deoxynucleotide hybrids with mRNA are not substrates for
ribonuclease H and in one case only has sequence-specific
antisense inhibition of cell free protein synthesis been report-
ed in which the target was a 5' upstream untranslated cap
region of the mRNA (Bertrand et al., 1989). Phosphoro-
thioate oligodeoxynucleotide analogues, in which an unlinked
oxygen on phosphorus of the internucleoside linkage is
replaced by sulphur, are readily soluble and comparatively
resistant to nucleases, while retaining the capacity to activate
ribonuclease H cleavage of mRNA at the site of hybridisa-
tion (Reviewed in Cohen, 1989). However, they may be taken
up poorly by cells, they exhibit lower hybridisation affinity
than phosphodiester oligodeoxynucleotides and are toxic in
themselves, inducing non-specific inhibition of protein syn-
thesis at concentrations which are uncomfortably close to
those required to achieve sequence specific antisense effects.
At the same time, significant inhibitory activity against HIV
replication has been achieved in cell culture using phos-
phorothioate oligodeoxynucleotide analogues, although the
effects were not always sequence specific. The therapeutic
potential of phosphorothioates as a treatment for AIDS is
currently under investigation. Nonionic methylphosphonate
oligodeoxynucleotide analogues, in which the acidic hydroxyl
of the phosphodiester linkage is replaced by a methyl group,
are non-toxic, nuclease resistant, and being somewhat
lipophilic are apparently able to permeate cells by simple
diffusion (Miller & Ts'o, 1987). However, these analogues
hybridise poorly to complementary nucleic acids, do not
activate ribonuclease H cleavage of mRNA, and in the
absence of at least one contiguous phosphodiester linkage
exhibit rapidly decreasing solubility with increasing chain
length above 9 bases. Some advantage for cell culture work
may possibly be achieved by combining methylphos-
phonodiester and phosphodiester structures in chimeric
molecules, but it is unlikely that these would be of
therapeutic potential (Tidd, 1990).
It has been suggested that enhanced cell delivery of oligo-
deoxynucleotides may be achieved by linking them to poly-L-
lysine, cholesterol or lipophilic intercalating agents, or by
their encapsulation in liposomes (reviewed in Tidd, 1990).
Attached intercalating agents have also been reported to
enhance significantly the hybrid stability for short oligo-
nucleotides by intercalating between the adjacent base pairs.
However, short antisense oligonucleotides are likely to have
complementary sequences in other mRNAs in addition to the
target, and consequently, specificity may be compromised by
this approach. The general utility of such modifications has
yet to be established in a range of cell culture systems with
different gene targets. Other modifications to enhance the
activity of antisense oligodeoxynucleotides and oligodeoxy-
nucleotide analogues have included their crosslinking to
photoactivatable groups, chemically reactive groups, free
radical generating systems and ribonuclease (reviewed in
Tidd, 1990). These have been evaluated almost entirely in cell
free systems, and their general activity against intact cells is
yet to be determined.
Finally, normal phosphodiester polypurine and polypyrim-
idine oligodeoxynucleotides have been shown, in vitro, to
form colinear triplexes with polypurine:polypyrimidine
stretches in double stranded DNA, in which the oligodeoxy-
nucleotide occupies the major groove of the DNA helix
through Hoogsteen hydrogen bonding with the parallel poly-
purine strand. Formation of such a complex inhibited RNA
transcription from the human c-myc gene in vitro (Cooney et
al., 1988), but exploitation of this novel means of inhibiting
gene expression for therapeutic purposes, and possibly even
in its application to intact cultured cells, will require the
design of nuclease resistant oligodeoxynucleotide analogues
which, unlike methylphosphonates, retain the capacity for
triple helix formation with double stranded DNA (Kibler-
Herzog et al., 1990).
The present state of the art is that antisense oligodeoxy-
nucleotides or oligodeoxynucleotide analogues can appar-
ently inhibit gene expression when presented exogenously to
selected model intact cell systems, but no one structure yet
devised has proved to be universally applicable against a
variety of cultured cell types, and much less a potential
therapeutic agent. The immediate research priority must be
for more extensive biochemical investigations of the uptake
and interactions of oligonucleotides in intact cells in order to
gain an understanding of the factors affecting the efficacy of
these biopolymers. Only when will it be possible to design
improved structures on a rational basis. Hopefully, such
molecules may be used in vitro on a variety of tumour cell
lines to establish the general validity of what is still essen-
tially an hypothesis, that inhibition of activated oncogene
expression may lead to reversal of malignant transformation.
Although there is considerable optimism that research in this
area will lead to novel antiviral and cancer chemotherapeutic
agents in which oligonucleotides provide the specificity, the
pharmacological and financial considerations discussed by
Zon (1990) may well mean that the role of oligonucleotides8 D.M. TIDD
will be limited to defining gene targets in cell culture and that
other types of drug will be required to modulate these targets
clinically.
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